| Drug Name |
Tavaborole |
| Drug ID |
BADD_D02119 |
| Description |
Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu). |
| Indications and Usage |
Indicated for the treatment of onychomycosis (a fungal infection) of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. |
| Marketing Status |
approved; investigational |
| ATC Code |
D01AE24 |
| DrugBank ID |
DB09041
|
| KEGG ID |
D10169
|
| MeSH ID |
C512998
|
| PubChem ID |
11499245
|
| TTD Drug ID |
D05VGL
|
| NDC Product Code |
69575-4018; 68180-958; 10337-905; 69097-686; 72578-102; 62332-467; 69037-0034; 63629-8704; 69238-1657; 50909-1702; 69766-037; 58175-0614; 66039-932; 51862-690; 70771-1826; 0574-0157; 51672-1397 |
| UNII |
K124A4EUQ3
|
| Synonyms |
tavaborole | 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole | AN 2690 | AN2690 | AN-2690 | Kerydin |
